TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SV4FKJ3

Market Closed - Deutsche Boerse AG 01:17:03 08/06/2024 am IST
4.77 EUR +0.85% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month-10.00%
1 month+3.70%
Date Price Change
07/24/07 4.77 +0.85%
06/24/06 4.73 -2.87%
05/24/05 4.87 -0.20%
04/24/04 4.88 -5.24%
03/24/03 5.15 -2.83%

Delayed Quote Deutsche Boerse AG

Last update June 08, 2024 at 01:17 am IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SV4FKJ
ISINDE000SV4FKJ3
Date issued 18/04/2023
Strike 131.5 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.98
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.39
Lowest since issue 2.81

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
80.69 USD
Average target price
108.1 USD
Spread / Average Target
+33.96%
Consensus